Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial)

Background Detailed pharmacokinetics to guide oseltamivir (Tamiflu®) dosing in morbidly obese patients is lacking. Methods The OPTIMO trial was a single-centre, non-randomized, open-label pharmacokinetic study of single-dose and steady-state oral oseltamivir phosphate and its carboxylate metabolite...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2011-09, Vol.66 (9), p.2083-2091
Hauptverfasser:	Thorne-Humphrey, L. M., Goralski, K. B., Slayter, K. L., Hatchette, T. F., Johnston, B. L., McNeil, S. A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - pharmacokinetics Antiviral drugs Area Under Curve Biological and medical sciences Biotransformation Body Mass Index Dose-Response Relationship, Drug Double-Blind Method Drug dosages Female Half-Life Humans Male Medical sciences Metabolic diseases Middle Aged Obesity Obesity, Morbid - metabolism Oseltamivir - administration & dosage Oseltamivir - adverse effects Oseltamivir - pharmacokinetics Pharmacology. Drug treatments Prodrugs - pharmacokinetics Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Detailed pharmacokinetics to guide oseltamivir (Tamiflu®) dosing in morbidly obese patients is lacking. Methods The OPTIMO trial was a single-centre, non-randomized, open-label pharmacokinetic study of single-dose and steady-state oral oseltamivir phosphate and its carboxylate metabolite in healthy, morbidly obese [body mass index (BMI) > 40)] and healthy, non-obese (BMI
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/dkr257